Sofinnova Partners Announces Three New Investments From Its Fund Dedicated to Italian Scientific Research
Sofinnova Partners, a leading European life sciences venture capital firm, has announced today three new investments from the Sofinnova Telethon Fund. Its early-stage fund dedicates its investments to rare, genetic diseases. The startups, AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics, are developing promising new therapies for rare, genetic diseases.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and also in Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise.
Meanwhile, the Sofinnova Telethon Fund is the largest of its kind that dedicates its entire fund to biotechnolog…